uterine cancer, ovarian cancer
Conditions
Interventions
Aprepitant on days 1 to 3 (or fosapreitant on day1) Granisetron on day 1 Dexamethasone on days 1 to 4
Granisetron on day 1 Dexamethasone on days 1 to 4
Sponsors
Nagasaki University (graduate school) department of Obstetrics and Gynecology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patient is scheduled to receive her first course of paclitaxel/carboplatin or docetaxel/carboplatin for gynecological cancer 2) Patient has not received highly or moderately emetogenic chemotherapy 3) Patient is able to sign to an approved informed consent 4) Patient is able to mention a diary
Exclusion criteria
Exclusion criteria: 1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 48 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is scheduled to receive radiation therapy to the abdomen 6) Patient has the collateral symptom that the dosage of the dexamethasone is impossible for four days 7) Patient has received Pimozide 8) Patient is judged inappropriate by the investigator as subject for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with No Emesis in overall phase (0-120 hours after administration of carboplatin on day 1) | — |
Countries
Japan
Contacts
Public ContactShuhei Abe
Nagasaki University (graduate school) Department of Obstetrics and Gynecology
Outcome results
None listed